T1	Participants 41 106	cetuximab-treated patients with advanced colorectal cancer (ACRC)
T2	Participants 437 474	cetuximab-treated patients with ACRC.
T3	Participants 773 888	five hundred and seventy-two patients were included; 41% were â‰¥ 65 years and 25% had comorbidities at randomization
T4	Participants 1289 1305	Elderly patients
T5	Participants 1059 1115	patients with greater comorbidity in univariate analysis
T6	Participants 1390 1423	Patients with greater comorbidity
T7	Participants 1581 1603	patients with good PS,
